Preferences help
enabled [disable] Abstract
Number of results
2009 | 4 | 1 | 54-58
Article title

Uterine leiomyoma with massive lymphoid infiltrate after colon cancer chemotherapy: an immunohistochemical investigation with special reference to lysosome-associated membrane protein expression

Title variants
Languages of publication
Uterine leiomyoma with massive lymphoid infiltration is a rare morphologic phenomenon. We describe the first case of uterine leiomyoma with lymphoid infiltration observed in a patient after chemotherapy for sigmoid cancer. We performed immunohistochemical analysis with a panel of antibodies to several markers. Detection of CD20, CD3, Ki67, CD68 and Epstein-Barr virus nuclear antigen assisted in the differential diagnosis and partial elucidation of the pathogenesis. In addition, we examined the lysosome-associated membrane proteins LAMP-1 and LAMP-2 for the first time in this lesion. Their expression was elevated, indicating enhanced autophagy, an indirect sign of degenerative changes in this benign tumor characterized by massive lymphoid infiltration.
Physical description
1 - 3 - 2009
11 - 2 - 2009
  • Department of General and Clinical Pathology, Medical University of Plovdiv, 4002, Plovdiv, Bulgaria
  • Service d’Anatomie et de Cytologie Pathologiques, Centre Hospitalier de Lagny-Marne La-Vallée, 77405, Lagny-Sur-Marne, France
  • Service d’Anatomie et de Cytologie Pathologiques, Centre Hospitalier de Lagny-Marne La-Vallée, 77405, Lagny-Sur-Marne, France
  • Département de Pathologie, Hôpital Henri Mondor, 94010, Créteil, France
  • Department of Biology, Medical University of Plovdiv, 4002, Plovdiv, Bulgaria
  • [1] Paik S.S., Oh Y.H., Jang K.S., Han H.X., Cho S.H., Uterine leiomyoma with massive lymphoid infiltration: case report and review of the literature, Pathol. Int., 2004, 54, 343–348[Crossref]
  • [2] Wei S., Feng R., Cui Q., Luo Y., Zhang S., Uterine adenomyoma with lymphoid infiltration simulating lymphoma, Gynecol. Oncol., 2004, 95, 409–411[Crossref]
  • [3] Saglam A., Guler G., Taskin M., Ayhan A., Uner A., Uterine leiomyoma with prominent lymphoid infiltrate, Int. J. Gynecol. Cancer, 2005, 15, 167–170[Crossref]
  • [4] Ferry J.A., Harris N.L., Scully R.E., Uterine leiomyomas with lymphoid infiltration simulating lymphoma. A report of seven cases, Int. J. Gynecol. Pathol., 1989, 8, 263–270 [Crossref]
  • [5] Chuang S.S., Lin C.N., Li C.Y., Wu C.H., Uterine leiomyoma with massive lymphocytic infiltration simulating malignant lymphoma. A case report with immunohistochemical study showing that the infiltrating lymphocytes are cytotoxic T cells, Pathol. Res. Pract., 2001, 197, 135–138
  • [6] Botsis D., Trakakis E., Kondis-Pafitis A., Kontoravdis A., Kassanos D., Chryssikopoulos A. et al., Leiomyoma of the uterus with massive lymphoid infiltration simulating lymphoma. A case report, Eur. J. Gynaecol. Oncol., 1999, 20, 61–62
  • [7] McClean G., McCluggage W.G., Unusual morphologic features of uterine leiomyomas treated with gonadotropin-releasing hormone agonists: massive lymphoid infiltration and vasculitis, Int. J. Surg. Pathol., 2003, 11, 339–344[Crossref]
  • [8] Ohmori T., Wakamoto R., Lu L.M., Okada K., M. Nose M., Immunohistochemical study of a case of uterine leiomyoma showing massive lymphoid infiltration and localized vasculitis after LH-RH derivant treatment, Histopathology, 2002, 41, 276–277[Crossref]
  • [9] Bardseley V., Cooper P., Peat D., Massive lymphocytic infiltration of uterine leiomyomas associated with GnRN agonist treatment, Histopathology, 1998, 33, 80–83[Crossref]
  • [10] Crow J., Gardner R.L., McSweeney G., Shaw R.W., Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin, Int. J. Gynecol. Pathol., 1995, 14, 235–242[Crossref]
  • [11] Resta L., Sanguedolce F., Orsini, G., Laricchia L., Piscitelli D., Fiore M.G., Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents, Pathologica, 2004, 96, 35–41
  • [12] Colgan T.J., Pendergast S., LeBlanc M., The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues, Hum. Pathol., 1993, 24, 1073–1077[Crossref]
  • [13] Ito F., Kawamura N., Ichimura T., Tsujimura A., Ishiko O., Ogita S., Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment, Fertil. Steril., 2001, 75, 125–130[Crossref]
  • [14] Bozzini N., Rodrigues C., Petti D., Bevilacqua R., Goncalves, S., Pinotti J., Efects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure, Acta Obstet. Gynecol. Scan., 2003 82, 330–334[Crossref]
  • [15] Ueda M., Kumagai K., Ueki K., Inoki C., Orino I., Ueki M., Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil, Int. J. Cancer, 1997, 71, 668–674<668::AID-IJC25>3.0.CO;2-6[Crossref]
  • [16] Laforga J., Aranda F., Uterine leiomyoma with T-cell infiltration associated with GnRH agonist goserelin, Histopathology, 1999, 34, 471–472[Crossref]
  • [17] Yoshimatsu K., Kuhara K., Itagaki, H. Aizawa M., Yokomizo H., Fujimoto T., et al., Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer, Anticancer Res., 2008, 21, 373–378
  • [18] Cuervo A.M., Dice J.F., Unique properties of lamp 2 compared to other lamp 2 isoforms, J. Cell. Sci., 2000, 24, 4441–4450
  • [19] Sarafian V., Dikov D., LAMPs and ABH histo-blood group antigens in granulation tissue, APMIS, 2007, 114, 701–706[WoS][Crossref]
  • [20] Gozuacik D., Kimchi A., Autophagy as a cell death and tumor suppressor mechanism, Oncogene, 2004, 23, 2891–2906[Crossref]
  • [21] Huang J., Klionsky D.J., Autophagy and human disease, Cell Cycle, 2007, 6, 1837–1849 [Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.